{"gene":"COXFA4L2","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2011,"finding":"NDUFA4L2 (COXFA4L2) is a HIF-1α target gene whose hypoxia-induced expression attenuates mitochondrial oxygen consumption by inhibiting Complex I activity, thereby limiting intracellular ROS production under low-oxygen conditions. This was demonstrated using NDUFA4L2-silenced cells and NDUFA4L2 knockout murine embryonic fibroblasts.","method":"RNAi silencing, NDUFA4L2 knockout MEFs, oxygen consumption assays, Complex I activity assay","journal":"Cell Metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function (siRNA + KO MEFs) with defined cellular phenotype (O2 consumption, Complex I activity, ROS), replicated across multiple cell systems in a single rigorous study","pmids":["22100406"],"is_preprint":false},{"year":2017,"finding":"NDUFA4L2 overexpression in H9c2 cardiomyocytes subjected to hypoxia/reperfusion prevents apoptosis and mitochondrial dysfunction (increased ATP, delayed mPTP opening, reduced cytochrome c release) via inhibition of Complex I activity; silencing Complex I itself recapitulates the cardioprotective effect.","method":"Overexpression and knockdown in H9c2 cells, flow cytometry apoptosis, western blot (Bax/Bcl-2), ATP measurement, mPTP opening assay, cytochrome c detection","journal":"Clinical and Experimental Pharmacology & Physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal functional assays in a single lab with epistasis (Complex I silencing rescues phenotype), no independent replication","pmids":["28429857"],"is_preprint":false},{"year":2018,"finding":"HIF-1α directly binds the hypoxia response element (HRE) of the NDUFA4L2 promoter to transcriptionally activate NDUFA4L2 in cardiac stem cells, and this signaling promotes CSC survival under hypoxia; knockdown of NDUFA4L2 reverses the survival benefit.","method":"ChIP assay (HIF-1α binding to NDUFA4L2 HRE), HIF-1α agonist/inhibitor (DMOG/2-ME) treatment, NDUFA4L2 siRNA knockdown, cell viability assay","journal":"Biochemical and Biophysical Research Communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP assay directly demonstrates HIF-1α binding to NDUFA4L2 HRE, combined with pharmacological and genetic manipulation; single lab","pmids":["29953852"],"is_preprint":false},{"year":2019,"finding":"NDUFA4L2 attenuates apoptosis of nucleus pulposus cells under oxidative stress by suppressing excessive mitophagy; TBHP-induced oxidative stress decreases HIF-1α/NDUFA4L2 signaling to promote mitophagy and apoptosis, whereas NDUFA4L2 upregulation blocks this pathway.","method":"Primary human NP cell culture, TBHP oxidative stress model, mitophagy inhibitor rescue, NDUFA4L2 overexpression/knockdown, flow cytometry apoptosis, in vivo IVDD model","journal":"Experimental & Molecular Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with pharmacological inhibitor rescue; single lab, multiple methods","pmids":["31740659"],"is_preprint":false},{"year":2021,"finding":"Ectopic NDUFA4L2 expression in mouse skeletal muscle reduces mitochondrial respiration and ROS production, lowers AMP, ADP, ATP, and NAD+ levels without altering ETC protein content, causes ~20% reduction in muscle mass, and induces atrogene (MuRF1, Mul1) and apoptotic gene (caspase 3, Bax) expression; femoral artery ligation induces endogenous NDUFA4L2 and its expression correlates with reduced muscle force.","method":"Adenovirus-mediated ectopic NDUFA4L2 expression in vivo, in vivo electroporation, femoral artery ligation model, mitochondrial respiration assay, metabolite quantification (AMP/ADP/ATP/NAD+), muscle mass and force measurements, gene expression analysis","journal":"FASEB Journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo gain-of-function with multiple orthogonal phenotypic and biochemical readouts, corroborated by an in vivo disease model (FAL), single lab but comprehensive","pmids":["34724256"],"is_preprint":false},{"year":2021,"finding":"NDUFA4L2 overexpression in HER2-positive breast cancer cells facilitates mitochondrial relocalization of HER2 and suppresses ROS production, thereby promoting trastuzumab resistance; mitochondrial localization of NDUFA4L2 was confirmed by immunofluorescence and subcellular fractionation western blot.","method":"Immunofluorescence and mitochondrial fractionation western blot (localization), Seahorse metabolic assay, DCFDA ROS measurement, NDUFA4L2 overexpression, trastuzumab resistance assay","journal":"Therapeutic Advances in Medical Oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiment tied to functional consequence (trastuzumab resistance) with multiple metabolic assays; single lab","pmids":["34276814"],"is_preprint":false},{"year":2022,"finding":"NFIB transcription factor binds to the promoter region of NDUFA4L2 and promotes its transcription in hepatocellular carcinoma cells; this transcriptional upregulation of NDUFA4L2 inhibits sorafenib-induced ROS accumulation, driving sorafenib resistance.","method":"Gene expression profiling, promoter binding assay (NFIB binding to NDUFA4L2 promoter), NFIB knockdown, NDUFA4L2 expression measurement, ROS assay, in vitro and in vivo tumor models","journal":"Cancer Science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding demonstrated, combined with functional ROS and drug resistance readouts; single lab","pmids":["36369883"],"is_preprint":false},{"year":2022,"finding":"In mouse and human brain, NDUFA4L2 is constitutively and specifically expressed in pericytes (highest) and mural cells; its expression is regulated by PHD2/PHD3-dependent HIF stabilization (Vhl conditional knockout dramatically induces expression). NDUFA4L2 inactivation in pericytes increases oxygen consumption and enhances HIF pathway induction under hypoxia, establishing that NDUFA4L2 couples mitochondrial O2 consumption to the cellular hypoxia response in pericytes.","method":"scRNA-seq analysis, multiplexed fluorescence RNA in situ hybridization, Ng2-cre Vhl conditional knockout mice, in vitro human brain pericyte culture, oxygen consumption assay, HIF pathway reporter readout","journal":"Journal of Cerebral Blood Flow and Metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific localization by FISH + genetic loss-of-function in vivo with oxygen consumption and HIF pathway phenotype; multiple orthogonal methods","pmids":["35929074"],"is_preprint":false},{"year":2022,"finding":"NXPH4 promotes stability of NDUFA4L2 protein in bladder cancer cells; increased NDUFA4L2 levels downstream of NXPH4 activate ROS and glycolysis, contributing to gemcitabine resistance. Rescue experiments show NDUFA4L2 is required for NXPH4-regulated functions.","method":"Rescue assays (NDUFA4L2 re-expression in NXPH4-knockdown cells), glycolytic activity assay, ROS measurement, in vivo xenograft validation","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — epistatic rescue experiments place NDUFA4L2 downstream of NXPH4; validated in vivo; single lab","pmids":["35954445"],"is_preprint":false},{"year":2023,"finding":"NDUFA4L2 expression in ccRCC cells induces a Warburg-like metabolic shift (increased extracellular acidification rate, decreased oxygen consumption rate). Mass-spectrometry-based proteomics of NDUFA4L2-associated complexes identified 3,215 co-immunoprecipitated proteins, with top pathways including 'Metabolic Reprogramming in Cancer' and 'Warburg Effect.' NDUFA4L2 enhances mitochondrial fragmentation and increases mitochondrial-lysosomal associations; 161 lysosomal proteins including NPC1 and NPC2 associate with NDUFA4L2, and NDUFA4L2 regulates lysosomal size and abundance.","method":"CRISPR-Cas9 NDUFA4L2 knockout (RCC4-KO), MS-based proteomics of immunoprecipitated NDUFA4L2 complexes, Seahorse metabolic assay, high-resolution fluorescence microscopy and live cell imaging","journal":"Cancer Biology & Therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS proteomics of co-IP complexes with CRISPR KO comparator and orthogonal live imaging; single lab","pmids":["36722045"],"is_preprint":false},{"year":2024,"finding":"Lenvatinib increases NDUFA4L2 expression in HCC cells, leading to increased IL-33 production and secretion; IL-33 triggers neutrophil extracellular trap (NET) formation via Akt/mTOR-dependent PADI4 upregulation. This NDUFA4L2→IL-33→PADI4/NET axis inhibits cuproptosis in HCC cells and drives lenvatinib resistance.","method":"NDUFA4L2 expression manipulation in HCC cells, IL-33 knockdown, NETs measurement (CitH3, MPO-DNA, elastase, MPO activity), cuproptosis assay (copper content, FDX1, pyruvate), in vivo HCC mouse models, mTOR inhibitor (rapamycin) and PADI4 inhibitor (GSK484)","journal":"Cellular Oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multi-step pathway validated with genetic and pharmacological interventions in vitro and in vivo; single lab","pmids":["39585643"],"is_preprint":false},{"year":2024,"finding":"miR-183-5p directly targets NDUFA4L2 mRNA and negatively regulates its expression; this reduces NDUFA4L2-mediated suppression of mitochondrial Complex I activity, leading to mitoROS accumulation and suppression of lung squamous cell carcinoma cell survival in vitro and in vivo.","method":"miR-183-5p overexpression, NDUFA4L2 knockdown, mitoROS measurement, Complex I activity assay, apoptosis assay, in vivo xenograft model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct negative regulatory link (miR-183-5p→NDUFA4L2→Complex I→mitoROS) validated by multiple functional assays and in vivo; single lab","pmids":["39154121"],"is_preprint":false},{"year":2026,"finding":"COXFA4L2 is a paralog of COXFA4 (formerly NDUFA4), a nuclear-encoded cytochrome c oxidase (Complex IV) subunit. In patient-derived fibroblasts from individuals with biallelic COXFA4-null variants (Leigh-like encephalopathy), COXFA4L2 is upregulated and compensates for loss of COXFA4, preserving residual COX activity; this identifies a paralog-mediated compensatory mechanism at Complex IV.","method":"Patient-derived fibroblast studies (13 individuals, 12 families), COX activity assay, COXFA4L2 protein quantification, COX assembly analysis","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct biochemical assays in human patient-derived cells showing COXFA4L2 upregulation compensates for COXFA4 loss with preserved COX activity; large genetically confirmed cohort","pmids":["42218136"],"is_preprint":false},{"year":2026,"finding":"Ndufa4l2 activates the PI3K/AKT signaling pathway in retinal Müller cells under ischemic/hypoxic stress, driving reactive gliosis, hyper-proliferation, and enhanced migration; pharmacological PI3K inhibition (LY294002) reverses these Ndufa4l2-induced effects.","method":"scRNA-seq (OIR mouse model), CRISPR/Cas9 knockout and overexpression of Ndufa4l2, bioinformatics pathway analysis, PI3K inhibitor (LY294002) rescue experiments, in vitro and in vivo validation","journal":"Pathology, Research and Practice","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with pharmacological epistasis (PI3K inhibitor rescue) validating PI3K/AKT as downstream effector; single lab","pmids":["42235340"],"is_preprint":false},{"year":2016,"finding":"NDUFA4L2 is HIF-1-regulated in HCC cells; inactivation of NDUFA4L2 increases mitochondrial activity and oxygen consumption, resulting in ROS accumulation and apoptosis. Knockdown of NDUFA4L2 suppresses HCC growth and metastasis in an orthotopic in vivo model.","method":"NDUFA4L2 knockdown (siRNA), oxygen consumption measurement, ROS assay, apoptosis assay, orthotopic HCC mouse model, HIF inhibitor (digoxin) treatment","journal":"Clinical Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with multiple orthogonal metabolic and phenotypic readouts, in vivo validation; single lab","pmids":["26819450"],"is_preprint":false},{"year":2017,"finding":"ELK1 transcription factor positively regulates NDUFA4L2 expression in ccRCC cells; ELK1 knockdown reduces NDUFA4L2 expression, and ELK1 levels positively correlate with NDUFA4L2 in ccRCC clinical tissues.","method":"ELK1 knockdown in ccRCC cells, NDUFA4L2 expression measurement by western blot/qPCR, correlation analysis in clinical samples","journal":"PeerJ","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single knockdown experiment demonstrating ELK1→NDUFA4L2 regulation; single lab, single method","pmids":["29158991"],"is_preprint":false},{"year":2020,"finding":"In hypoxic pulmonary artery smooth muscle cells, NDUFA4L2 (downstream of HIF-1α) promotes ROS-mediated lipid peroxidation (MDA and 4-HNE accumulation) and activates a p38–5-lipoxygenase downstream signaling pathway to drive PASMC proliferation and vascular remodeling; siNDUFA4L2 blocks these effects.","method":"NDUFA4L2 siRNA knockdown in human PASMCs, MDA/4-HNE measurement, ROS assay, 5-LO/p38 pathway western blot, in vivo hypoxic PAH rat model","journal":"Journal of Cellular and Molecular Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with multiple pathway-specific biochemical readouts (ROS, lipid peroxides, p38-5-LO); in vivo model corroboration; single lab","pmids":["33340241"],"is_preprint":false},{"year":2021,"finding":"Ndufa4l2 knockdown in renal proximal tubules of a TRACK mouse model reduces neutral lipid accumulation and decreases expression of ccRCC markers carbonic anhydrase 9 (CA9) and Enolase 1 (ENO1), linking mitochondrial NDUFA4L2 to lipid deposition and ccRCC marker expression.","method":"Dox-inducible shRNA-mediated knockdown of Ndufa4l2 in transgenic mouse kidney (TRACK model), lipid staining, CA9 and ENO1 protein quantification","journal":"Frontiers in Oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo tissue-specific knockdown with defined biochemical phenotype; single lab, single genetic model","pmids":["34970493"],"is_preprint":false}],"current_model":"COXFA4L2 (NDUFA4L2) is a nuclear-encoded mitochondrial protein whose expression is transcriptionally induced by HIF-1α (via HRE binding) and additional transcription factors (ELK1, NFIB); it functions primarily as an inhibitor of mitochondrial respiratory Complex I activity to reduce oxygen consumption and ROS production under hypoxia, acts as a compensatory paralog of COXFA4 at Complex IV when COXFA4 is lost, regulates mitochondrial fragmentation and mitochondrial-lysosomal associations, promotes a Warburg-like metabolic shift, and activates downstream signaling (PI3K/AKT, p38-5-LO) to influence cell survival, muscle mass, vascular remodeling, and cancer drug resistance."},"narrative":{"mechanistic_narrative":"COXFA4L2 (NDUFA4L2) is a nuclear-encoded mitochondrial protein that serves as a hypoxia-driven brake on oxidative metabolism, restraining electron transport chain activity to limit oxygen consumption and reactive oxygen species (ROS) production [PMID:22100406, PMID:35929074]. Its expression is a direct transcriptional output of the HIF pathway: HIF-1α binds the hypoxia response element of the NDUFA4L2 promoter [PMID:29953852], and PHD2/PHD3-dependent HIF stabilization controls its constitutive, cell-type-restricted expression in brain pericytes and mural cells, where loss of the protein raises oxygen consumption and amplifies the cellular hypoxia response [PMID:35929074]. Mechanistically, COXFA4L2 inhibits respiratory Complex I activity without altering ETC protein content, and its loss restores Complex I flux with consequent mitoROS accumulation and apoptosis [PMID:22100406, PMID:34724256, PMID:39154121]. This metabolic restraint produces a Warburg-like shift toward glycolysis and reshapes mitochondrial dynamics, promoting mitochondrial fragmentation and mitochondrial–lysosomal associations [PMID:36722045]. Across many disease settings the same ROS-suppressive function is co-opted: it confers cytoprotection in cardiomyocytes and cardiac stem cells under hypoxia/reperfusion [PMID:28429857, PMID:29953852], drives proliferation and vascular remodeling in pulmonary artery smooth muscle cells via a p38–5-lipoxygenase axis [PMID:33340241], promotes reactive gliosis through PI3K/AKT signaling in retinal Müller cells [PMID:42235340], and underlies tumor growth and resistance to multiple anticancer agents by suppressing ROS-mediated cell death [PMID:34276814, PMID:36369883, PMID:26819450]. Beyond its respiratory inhibitory role, COXFA4L2 is a paralog of the Complex IV subunit COXFA4 (NDUFA4) and is upregulated to functionally compensate for COXFA4 loss, preserving residual cytochrome c oxidase activity in patient-derived fibroblasts from individuals with biallelic COXFA4-null Leigh-like encephalopathy [PMID:42218136].","teleology":[{"year":2011,"claim":"Established the founding mechanism: how does a HIF target gene help cells survive hypoxia metabolically? COXFA4L2 was shown to inhibit Complex I, lowering O2 consumption and ROS.","evidence":"RNAi silencing and knockout MEFs with oxygen consumption and Complex I activity assays","pmids":["22100406"],"confidence":"High","gaps":["Molecular basis of Complex I inhibition (binding site, stoichiometry) not defined","Does not address whether the protein associates with Complex I or acts indirectly"]},{"year":2016,"claim":"Tested whether the ROS-suppressive function is exploited by tumors; NDUFA4L2 inactivation raised mitochondrial activity, ROS, and apoptosis and impaired HCC growth/metastasis.","evidence":"siRNA knockdown, oxygen consumption/ROS/apoptosis assays, orthotopic HCC mouse model, HIF inhibitor","pmids":["26819450"],"confidence":"Medium","gaps":["Direct molecular target within mitochondria not identified","Single lab"]},{"year":2018,"claim":"Resolved the direct transcriptional control: HIF-1α binds the NDUFA4L2 HRE to activate it, and this supports cell survival under hypoxia.","evidence":"ChIP for HIF-1α at the HRE, HIF agonist/inhibitor, siRNA knockdown and viability assays in cardiac stem cells","pmids":["29953852"],"confidence":"Medium","gaps":["Does not address additional transcription factor inputs","Single lab"]},{"year":2017,"claim":"Probed cytoprotection mechanism in cardiomyocytes; overexpression prevented hypoxia/reperfusion apoptosis and mitochondrial dysfunction, with Complex I silencing recapitulating the effect to establish epistasis.","evidence":"Overexpression/knockdown in H9c2 cells with apoptosis, ATP, mPTP, and cytochrome c assays","pmids":["28429857"],"confidence":"Medium","gaps":["No in vivo cardiac validation","Not independently replicated"]},{"year":2017,"claim":"Began mapping upstream regulators beyond HIF; ELK1 was shown to positively regulate NDUFA4L2 in ccRCC.","evidence":"ELK1 knockdown with NDUFA4L2 readout and clinical correlation","pmids":["29158991"],"confidence":"Low","gaps":["Single knockdown experiment, single method","No direct promoter binding demonstrated"]},{"year":2019,"claim":"Extended the survival role to oxidative-stress contexts; NDUFA4L2 limits apoptosis by suppressing excessive mitophagy in nucleus pulposus cells.","evidence":"Primary NP cells, TBHP oxidative stress, mitophagy inhibitor rescue, gain/loss of function, in vivo IVDD model","pmids":["31740659"],"confidence":"Medium","gaps":["Mechanistic link between Complex I inhibition and mitophagy regulation not defined","Single lab"]},{"year":2020,"claim":"Identified a downstream signaling consequence of NDUFA4L2-driven ROS; in PASMCs it engages a p38–5-lipoxygenase pathway and lipid peroxidation to drive proliferation and vascular remodeling.","evidence":"siRNA knockdown in human PASMCs, MDA/4-HNE/ROS assays, p38-5-LO western blots, hypoxic PAH rat model","pmids":["33340241"],"confidence":"Medium","gaps":["How ROS selectively activates p38-5-LO unclear","Single lab"]},{"year":2021,"claim":"Demonstrated direct mitochondrial localization tied to function; NDUFA4L2 facilitates HER2 mitochondrial relocalization and suppresses ROS to drive trastuzumab resistance.","evidence":"Immunofluorescence and mitochondrial fractionation, Seahorse, DCFDA ROS, overexpression, resistance assays","pmids":["34276814"],"confidence":"Medium","gaps":["Direct physical interaction with HER2 not established","Single lab"]},{"year":2021,"claim":"Provided in vivo gain-of-function evidence in skeletal muscle, linking metabolic restraint to muscle wasting; ectopic expression reduced respiration/ROS, depleted nucleotide pools, and caused muscle mass loss with atrogene/apoptotic gene induction.","evidence":"Adenoviral/electroporation expression in mouse muscle, femoral artery ligation, respiration and metabolite measurements, muscle force","pmids":["34724256"],"confidence":"High","gaps":["Whether endogenous induction reaches pathogenic thresholds in disease unclear","Molecular trigger of atrogene program not defined"]},{"year":2021,"claim":"Connected NDUFA4L2 to the ccRCC phenotype in vivo; knockdown reduced renal lipid accumulation and ccRCC markers CA9 and ENO1.","evidence":"Dox-inducible shRNA knockdown in TRACK transgenic mouse kidney, lipid staining, marker quantification","pmids":["34970493"],"confidence":"Medium","gaps":["Causal mechanism linking respiration inhibition to lipid deposition not resolved","Single genetic model"]},{"year":2022,"claim":"Defined cell-type-specific expression and its physiological coupling to hypoxia sensing; NDUFA4L2 is pericyte/mural-cell enriched, PHD2/3-HIF controlled, and tunes O2 consumption against the HIF response.","evidence":"scRNA-seq, multiplexed FISH, Ng2-cre Vhl conditional knockout, pericyte O2 consumption and HIF reporter assays","pmids":["35929074"],"confidence":"High","gaps":["Physiological role in neurovascular function not directly tested","Does not address Complex I vs other respiratory targets in pericytes"]},{"year":2022,"claim":"Added transcriptional and post-translational regulators in cancer; NFIB binds the promoter to induce NDUFA4L2 (sorafenib resistance), and NXPH4 stabilizes the protein to drive glycolysis/ROS (gemcitabine resistance).","evidence":"Promoter binding assays, NFIB and NXPH4 knockdown with rescue, ROS/glycolysis assays, in vivo tumor models","pmids":["36369883","35954445"],"confidence":"Medium","gaps":["Mechanism of NXPH4-mediated protein stabilization unknown","Direct vs indirect promoter binding by NFIB not fully resolved"]},{"year":2023,"claim":"Broadened the cellular role beyond Complex I; proteomics and imaging linked NDUFA4L2 to a Warburg-like shift, mitochondrial fragmentation, and mitochondrial-lysosomal associations including NPC1/NPC2.","evidence":"CRISPR KO (RCC4), co-IP MS proteomics, Seahorse, high-resolution live-cell microscopy","pmids":["36722045"],"confidence":"Medium","gaps":["The very large co-IP interactome (3,215 proteins) lacks specificity filtering for direct partners","Functional significance of NPC1/NPC2 association not tested"]},{"year":2024,"claim":"Uncovered new downstream effector axes; miR-183-5p directly targets NDUFA4L2 to release Complex I and raise mitoROS in LUSC, and a NDUFA4L2→IL-33→PADI4/NET axis inhibits cuproptosis to drive lenvatinib resistance in HCC.","evidence":"miR overexpression/knockdown with Complex I and mitoROS assays; IL-33/NET/cuproptosis assays with mTOR and PADI4 inhibitors, in vivo HCC models","pmids":["39154121","39585643"],"confidence":"Medium","gaps":["How NDUFA4L2 induces IL-33 production mechanistically unclear","Single lab for each axis"]},{"year":2026,"claim":"Revealed a distinct Complex IV role; as a COXFA4 paralog, COXFA4L2 is upregulated to compensate for COXFA4 loss and preserve COX activity in COXFA4-null patient cells.","evidence":"Patient-derived fibroblasts (13 individuals), COX activity and assembly assays, COXFA4L2 protein quantification","pmids":["42218136"],"confidence":"High","gaps":["Whether COXFA4L2 is a constitutive Complex IV subunit or only a compensatory substitute unclear","Relationship between Complex I inhibitory and Complex IV roles not reconciled"]},{"year":2026,"claim":"Established a signaling output in retinal disease; Ndufa4l2 activates PI3K/AKT to drive Muller cell gliosis, proliferation, and migration under ischemia.","evidence":"scRNA-seq (OIR model), CRISPR KO/overexpression, PI3K inhibitor (LY294002) rescue, in vitro and in vivo validation","pmids":["42235340"],"confidence":"Medium","gaps":["How a mitochondrial respiratory regulator activates PI3K/AKT not defined","Single lab"]},{"year":null,"claim":"The structural and biochemical basis by which COXFA4L2 inhibits Complex I versus functions at Complex IV remains unresolved, as does how a single mitochondrial protein produces such diverse downstream signaling (PI3K/AKT, p38-5-LO, IL-33/NET) outputs.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure or direct binding partner within Complex I established","Whether respiratory inhibition and Complex IV compensation are the same protein pool unknown","Mechanism linking metabolic restraint to specific cytoplasmic signaling cascades unclear"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,11]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[12]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,5,9]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,9,4]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[0,7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[12,14,16]}],"complexes":["Mitochondrial respiratory Complex I (inhibitory regulator)","Cytochrome c oxidase / Complex IV (compensatory subunit)"],"partners":["COXFA4","NXPH4","HER2","NPC1","NPC2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NRX3","full_name":"Cytochrome c oxidase hypoxia associated subunit FA4L2","aliases":["NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2","NADH-ubiquinone oxidoreductase MLRQ subunit homolog","NUOMS"],"length_aa":87,"mass_kda":10.0,"function":"Mitochondrial protein that plays a regulatory role in cellular metabolism, particularly under hypoxic conditions (PubMed:22100406). Downregulates mitochondrial respiratory chain complex I activity under hypoxia, reduces oxygen consumption and ROS and helps cells adapt by switching to glycolysis (PubMed:22100406)","subcellular_location":"Mitochondrion inner membrane","url":"https://www.uniprot.org/uniprotkb/Q9NRX3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"NDUFA4L2","url":"https://depmap.org/portal/gene/NDUFA4L2","classification":"Not Classified","n_dependent_lines":20,"n_total_lines":1208,"dependency_fraction":0.016556291390728478},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/COXFA4L2","total_profiled":1310},"omim":[],"hpa":{"profiled":true,"resolved_as":"NDUFA4L2","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":404.8},{"tissue":"esophagus","ntpm":399.1}],"url":"https://www.proteinatlas.org/search/NDUFA4L2"},"hgnc":{"alias_symbol":["NUOMS","FLJ26118","MISTRH"],"prev_symbol":["NDUFA4L2"]},"alphafold":{"accession":"Q9NRX3","domains":[{"cath_id":"-","chopping":"1-44","consensus_level":"medium","plddt":87.7373,"start":1,"end":44},{"cath_id":"-","chopping":"49-87","consensus_level":"medium","plddt":81.4923,"start":49,"end":87}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NRX3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NRX3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NRX3-F1-predicted_aligned_error_v6.png","plddt_mean":84.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=COXFA4L2","jax_strain_url":"https://www.jax.org/strain/search?query=COXFA4L2"},"sequence":{"accession":"Q9NRX3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NRX3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NRX3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NRX3"}},"corpus_meta":[{"pmid":"22100406","id":"PMC_22100406","title":"Induction of the mitochondrial NDUFA4L2 protein by HIF-1α decreases oxygen consumption by inhibiting Complex I activity.","date":"2011","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22100406","citation_count":309,"is_preprint":false},{"pmid":"30538212","id":"PMC_30538212","title":"Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma.","date":"2018","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/30538212","citation_count":193,"is_preprint":false},{"pmid":"31740659","id":"PMC_31740659","title":"Mitochondrial NDUFA4L2 attenuates the apoptosis of nucleus pulposus cells induced by oxidative stress via the inhibition of mitophagy.","date":"2019","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31740659","citation_count":98,"is_preprint":false},{"pmid":"26819450","id":"PMC_26819450","title":"NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/26819450","citation_count":77,"is_preprint":false},{"pmid":"33330441","id":"PMC_33330441","title":"NDUFA4L2 Regulated by HIF-1α Promotes Metastasis and Epithelial-Mesenchymal Transition of Osteosarcoma Cells Through Inhibiting ROS Production.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33330441","citation_count":33,"is_preprint":false},{"pmid":"30710412","id":"PMC_30710412","title":"Mitochondrial NDUFA4L2 protein promotes the vitality of lung cancer cells by repressing oxidative stress.","date":"2019","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30710412","citation_count":32,"is_preprint":false},{"pmid":"33340241","id":"PMC_33340241","title":"NDUFA4L2 in smooth muscle promotes vascular remodeling in hypoxic pulmonary arterial hypertension.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33340241","citation_count":26,"is_preprint":false},{"pmid":"29158991","id":"PMC_29158991","title":"NDUFA4L2 is associated with clear cell renal cell carcinoma malignancy and is regulated by ELK1.","date":"2017","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/29158991","citation_count":26,"is_preprint":false},{"pmid":"34276814","id":"PMC_34276814","title":"NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer.","date":"2021","source":"Therapeutic advances in medical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34276814","citation_count":22,"is_preprint":false},{"pmid":"35954445","id":"PMC_35954445","title":"NXPH4 Promotes Gemcitabine Resistance in Bladder Cancer by Enhancing Reactive Oxygen Species and Glycolysis Activation through Modulating NDUFA4L2.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35954445","citation_count":22,"is_preprint":false},{"pmid":"36369883","id":"PMC_36369883","title":"Transcriptional regulation of NDUFA4L2 by NFIB induces sorafenib resistance by decreasing reactive oxygen species in hepatocellular carcinoma.","date":"2022","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/36369883","citation_count":20,"is_preprint":false},{"pmid":"34724256","id":"PMC_34724256","title":"Mitochondrial NDUFA4L2 is a novel regulator of skeletal muscle mass and force.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/34724256","citation_count":18,"is_preprint":false},{"pmid":"39585643","id":"PMC_39585643","title":"Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma.","date":"2024","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/39585643","citation_count":17,"is_preprint":false},{"pmid":"36722045","id":"PMC_36722045","title":"NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma.","date":"2023","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36722045","citation_count":15,"is_preprint":false},{"pmid":"29953852","id":"PMC_29953852","title":"Induction of the mitochondrial NDUFA4L2 protein by HIF-1a regulates heart regeneration by promoting the survival of cardiac stem cell.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29953852","citation_count":14,"is_preprint":false},{"pmid":"34970493","id":"PMC_34970493","title":"Mitochondrial Ndufa4l2 Enhances Deposition of Lipids and Expression of Ca9 in the TRACK Model of Early Clear Cell Renal Cell Carcinoma.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34970493","citation_count":13,"is_preprint":false},{"pmid":"28429857","id":"PMC_28429857","title":"NDUFA4L2 protects against ischaemia/reperfusion-induced cardiomyocyte apoptosis and mitochondrial dysfunction by inhibiting complex I.","date":"2017","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28429857","citation_count":12,"is_preprint":false},{"pmid":"35929074","id":"PMC_35929074","title":"Unique expression of the atypical mitochondrial subunit NDUFA4L2 in cerebral pericytes fine tunes HIF activity in response to hypoxia.","date":"2022","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/35929074","citation_count":9,"is_preprint":false},{"pmid":"37841958","id":"PMC_37841958","title":"Hypoxia-induced the upregulation of NDUFA4L2 promoted colon adenocarcinoma progression through ROS-mediated PI3K/AKT pathway.","date":"2023","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/37841958","citation_count":8,"is_preprint":false},{"pmid":"39154121","id":"PMC_39154121","title":"MiR-183-5p inhibits lung squamous cell carcinoma survival through disrupting hypoxia adaptation mediated by HIF-1α/NDUFA4L2 axis.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39154121","citation_count":4,"is_preprint":false},{"pmid":"39747340","id":"PMC_39747340","title":"Nucleotide metabolism-associated drug resistance gene NDUFA4L2 promotes colon cancer progression and 5-FU resistance.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39747340","citation_count":4,"is_preprint":false},{"pmid":"39792315","id":"PMC_39792315","title":"A multidimensional pan-cancer analysis of NDUFA4L2 and verification of the oncogenic value in colon cancer.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/39792315","citation_count":2,"is_preprint":false},{"pmid":"39402288","id":"PMC_39402288","title":"Pancancer analysis of NDUFA4L2 with focused role in tumor progression and metastasis of colon adenocarcinoma.","date":"2024","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/39402288","citation_count":1,"is_preprint":false},{"pmid":"41787028","id":"PMC_41787028","title":"NDUFA4L2 regulates the progression and chemotherapy sensitivity of HNSCC by inhibiting PANoptosis.","date":"2026","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41787028","citation_count":0,"is_preprint":false},{"pmid":"39570435","id":"PMC_39570435","title":"Letter to the editor: the potential value of NDUFA4L2 in colon adenocarcinoma remains to be fully evaluated.","date":"2024","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/39570435","citation_count":0,"is_preprint":false},{"pmid":"42218136","id":"PMC_42218136","title":"COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy.","date":"2026","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/42218136","citation_count":0,"is_preprint":false},{"pmid":"42235340","id":"PMC_42235340","title":"Ndufa4l2 drives the pathological activation of Müller cells in ischemic retinopathy via the PI3K/AKT signaling pathway.","date":"2026","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/42235340","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":16503,"output_tokens":5076,"usd":0.062825,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13433,"output_tokens":5110,"usd":0.097458,"stage2_stop_reason":"end_turn"},"total_usd":0.160283,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"NDUFA4L2 (COXFA4L2) is a HIF-1α target gene whose hypoxia-induced expression attenuates mitochondrial oxygen consumption by inhibiting Complex I activity, thereby limiting intracellular ROS production under low-oxygen conditions. This was demonstrated using NDUFA4L2-silenced cells and NDUFA4L2 knockout murine embryonic fibroblasts.\",\n      \"method\": \"RNAi silencing, NDUFA4L2 knockout MEFs, oxygen consumption assays, Complex I activity assay\",\n      \"journal\": \"Cell Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function (siRNA + KO MEFs) with defined cellular phenotype (O2 consumption, Complex I activity, ROS), replicated across multiple cell systems in a single rigorous study\",\n      \"pmids\": [\"22100406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NDUFA4L2 overexpression in H9c2 cardiomyocytes subjected to hypoxia/reperfusion prevents apoptosis and mitochondrial dysfunction (increased ATP, delayed mPTP opening, reduced cytochrome c release) via inhibition of Complex I activity; silencing Complex I itself recapitulates the cardioprotective effect.\",\n      \"method\": \"Overexpression and knockdown in H9c2 cells, flow cytometry apoptosis, western blot (Bax/Bcl-2), ATP measurement, mPTP opening assay, cytochrome c detection\",\n      \"journal\": \"Clinical and Experimental Pharmacology & Physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal functional assays in a single lab with epistasis (Complex I silencing rescues phenotype), no independent replication\",\n      \"pmids\": [\"28429857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HIF-1α directly binds the hypoxia response element (HRE) of the NDUFA4L2 promoter to transcriptionally activate NDUFA4L2 in cardiac stem cells, and this signaling promotes CSC survival under hypoxia; knockdown of NDUFA4L2 reverses the survival benefit.\",\n      \"method\": \"ChIP assay (HIF-1α binding to NDUFA4L2 HRE), HIF-1α agonist/inhibitor (DMOG/2-ME) treatment, NDUFA4L2 siRNA knockdown, cell viability assay\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP assay directly demonstrates HIF-1α binding to NDUFA4L2 HRE, combined with pharmacological and genetic manipulation; single lab\",\n      \"pmids\": [\"29953852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NDUFA4L2 attenuates apoptosis of nucleus pulposus cells under oxidative stress by suppressing excessive mitophagy; TBHP-induced oxidative stress decreases HIF-1α/NDUFA4L2 signaling to promote mitophagy and apoptosis, whereas NDUFA4L2 upregulation blocks this pathway.\",\n      \"method\": \"Primary human NP cell culture, TBHP oxidative stress model, mitophagy inhibitor rescue, NDUFA4L2 overexpression/knockdown, flow cytometry apoptosis, in vivo IVDD model\",\n      \"journal\": \"Experimental & Molecular Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with pharmacological inhibitor rescue; single lab, multiple methods\",\n      \"pmids\": [\"31740659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Ectopic NDUFA4L2 expression in mouse skeletal muscle reduces mitochondrial respiration and ROS production, lowers AMP, ADP, ATP, and NAD+ levels without altering ETC protein content, causes ~20% reduction in muscle mass, and induces atrogene (MuRF1, Mul1) and apoptotic gene (caspase 3, Bax) expression; femoral artery ligation induces endogenous NDUFA4L2 and its expression correlates with reduced muscle force.\",\n      \"method\": \"Adenovirus-mediated ectopic NDUFA4L2 expression in vivo, in vivo electroporation, femoral artery ligation model, mitochondrial respiration assay, metabolite quantification (AMP/ADP/ATP/NAD+), muscle mass and force measurements, gene expression analysis\",\n      \"journal\": \"FASEB Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo gain-of-function with multiple orthogonal phenotypic and biochemical readouts, corroborated by an in vivo disease model (FAL), single lab but comprehensive\",\n      \"pmids\": [\"34724256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NDUFA4L2 overexpression in HER2-positive breast cancer cells facilitates mitochondrial relocalization of HER2 and suppresses ROS production, thereby promoting trastuzumab resistance; mitochondrial localization of NDUFA4L2 was confirmed by immunofluorescence and subcellular fractionation western blot.\",\n      \"method\": \"Immunofluorescence and mitochondrial fractionation western blot (localization), Seahorse metabolic assay, DCFDA ROS measurement, NDUFA4L2 overexpression, trastuzumab resistance assay\",\n      \"journal\": \"Therapeutic Advances in Medical Oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment tied to functional consequence (trastuzumab resistance) with multiple metabolic assays; single lab\",\n      \"pmids\": [\"34276814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NFIB transcription factor binds to the promoter region of NDUFA4L2 and promotes its transcription in hepatocellular carcinoma cells; this transcriptional upregulation of NDUFA4L2 inhibits sorafenib-induced ROS accumulation, driving sorafenib resistance.\",\n      \"method\": \"Gene expression profiling, promoter binding assay (NFIB binding to NDUFA4L2 promoter), NFIB knockdown, NDUFA4L2 expression measurement, ROS assay, in vitro and in vivo tumor models\",\n      \"journal\": \"Cancer Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding demonstrated, combined with functional ROS and drug resistance readouts; single lab\",\n      \"pmids\": [\"36369883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In mouse and human brain, NDUFA4L2 is constitutively and specifically expressed in pericytes (highest) and mural cells; its expression is regulated by PHD2/PHD3-dependent HIF stabilization (Vhl conditional knockout dramatically induces expression). NDUFA4L2 inactivation in pericytes increases oxygen consumption and enhances HIF pathway induction under hypoxia, establishing that NDUFA4L2 couples mitochondrial O2 consumption to the cellular hypoxia response in pericytes.\",\n      \"method\": \"scRNA-seq analysis, multiplexed fluorescence RNA in situ hybridization, Ng2-cre Vhl conditional knockout mice, in vitro human brain pericyte culture, oxygen consumption assay, HIF pathway reporter readout\",\n      \"journal\": \"Journal of Cerebral Blood Flow and Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific localization by FISH + genetic loss-of-function in vivo with oxygen consumption and HIF pathway phenotype; multiple orthogonal methods\",\n      \"pmids\": [\"35929074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NXPH4 promotes stability of NDUFA4L2 protein in bladder cancer cells; increased NDUFA4L2 levels downstream of NXPH4 activate ROS and glycolysis, contributing to gemcitabine resistance. Rescue experiments show NDUFA4L2 is required for NXPH4-regulated functions.\",\n      \"method\": \"Rescue assays (NDUFA4L2 re-expression in NXPH4-knockdown cells), glycolytic activity assay, ROS measurement, in vivo xenograft validation\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — epistatic rescue experiments place NDUFA4L2 downstream of NXPH4; validated in vivo; single lab\",\n      \"pmids\": [\"35954445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NDUFA4L2 expression in ccRCC cells induces a Warburg-like metabolic shift (increased extracellular acidification rate, decreased oxygen consumption rate). Mass-spectrometry-based proteomics of NDUFA4L2-associated complexes identified 3,215 co-immunoprecipitated proteins, with top pathways including 'Metabolic Reprogramming in Cancer' and 'Warburg Effect.' NDUFA4L2 enhances mitochondrial fragmentation and increases mitochondrial-lysosomal associations; 161 lysosomal proteins including NPC1 and NPC2 associate with NDUFA4L2, and NDUFA4L2 regulates lysosomal size and abundance.\",\n      \"method\": \"CRISPR-Cas9 NDUFA4L2 knockout (RCC4-KO), MS-based proteomics of immunoprecipitated NDUFA4L2 complexes, Seahorse metabolic assay, high-resolution fluorescence microscopy and live cell imaging\",\n      \"journal\": \"Cancer Biology & Therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS proteomics of co-IP complexes with CRISPR KO comparator and orthogonal live imaging; single lab\",\n      \"pmids\": [\"36722045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Lenvatinib increases NDUFA4L2 expression in HCC cells, leading to increased IL-33 production and secretion; IL-33 triggers neutrophil extracellular trap (NET) formation via Akt/mTOR-dependent PADI4 upregulation. This NDUFA4L2→IL-33→PADI4/NET axis inhibits cuproptosis in HCC cells and drives lenvatinib resistance.\",\n      \"method\": \"NDUFA4L2 expression manipulation in HCC cells, IL-33 knockdown, NETs measurement (CitH3, MPO-DNA, elastase, MPO activity), cuproptosis assay (copper content, FDX1, pyruvate), in vivo HCC mouse models, mTOR inhibitor (rapamycin) and PADI4 inhibitor (GSK484)\",\n      \"journal\": \"Cellular Oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multi-step pathway validated with genetic and pharmacological interventions in vitro and in vivo; single lab\",\n      \"pmids\": [\"39585643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"miR-183-5p directly targets NDUFA4L2 mRNA and negatively regulates its expression; this reduces NDUFA4L2-mediated suppression of mitochondrial Complex I activity, leading to mitoROS accumulation and suppression of lung squamous cell carcinoma cell survival in vitro and in vivo.\",\n      \"method\": \"miR-183-5p overexpression, NDUFA4L2 knockdown, mitoROS measurement, Complex I activity assay, apoptosis assay, in vivo xenograft model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct negative regulatory link (miR-183-5p→NDUFA4L2→Complex I→mitoROS) validated by multiple functional assays and in vivo; single lab\",\n      \"pmids\": [\"39154121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"COXFA4L2 is a paralog of COXFA4 (formerly NDUFA4), a nuclear-encoded cytochrome c oxidase (Complex IV) subunit. In patient-derived fibroblasts from individuals with biallelic COXFA4-null variants (Leigh-like encephalopathy), COXFA4L2 is upregulated and compensates for loss of COXFA4, preserving residual COX activity; this identifies a paralog-mediated compensatory mechanism at Complex IV.\",\n      \"method\": \"Patient-derived fibroblast studies (13 individuals, 12 families), COX activity assay, COXFA4L2 protein quantification, COX assembly analysis\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct biochemical assays in human patient-derived cells showing COXFA4L2 upregulation compensates for COXFA4 loss with preserved COX activity; large genetically confirmed cohort\",\n      \"pmids\": [\"42218136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Ndufa4l2 activates the PI3K/AKT signaling pathway in retinal Müller cells under ischemic/hypoxic stress, driving reactive gliosis, hyper-proliferation, and enhanced migration; pharmacological PI3K inhibition (LY294002) reverses these Ndufa4l2-induced effects.\",\n      \"method\": \"scRNA-seq (OIR mouse model), CRISPR/Cas9 knockout and overexpression of Ndufa4l2, bioinformatics pathway analysis, PI3K inhibitor (LY294002) rescue experiments, in vitro and in vivo validation\",\n      \"journal\": \"Pathology, Research and Practice\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with pharmacological epistasis (PI3K inhibitor rescue) validating PI3K/AKT as downstream effector; single lab\",\n      \"pmids\": [\"42235340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NDUFA4L2 is HIF-1-regulated in HCC cells; inactivation of NDUFA4L2 increases mitochondrial activity and oxygen consumption, resulting in ROS accumulation and apoptosis. Knockdown of NDUFA4L2 suppresses HCC growth and metastasis in an orthotopic in vivo model.\",\n      \"method\": \"NDUFA4L2 knockdown (siRNA), oxygen consumption measurement, ROS assay, apoptosis assay, orthotopic HCC mouse model, HIF inhibitor (digoxin) treatment\",\n      \"journal\": \"Clinical Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with multiple orthogonal metabolic and phenotypic readouts, in vivo validation; single lab\",\n      \"pmids\": [\"26819450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ELK1 transcription factor positively regulates NDUFA4L2 expression in ccRCC cells; ELK1 knockdown reduces NDUFA4L2 expression, and ELK1 levels positively correlate with NDUFA4L2 in ccRCC clinical tissues.\",\n      \"method\": \"ELK1 knockdown in ccRCC cells, NDUFA4L2 expression measurement by western blot/qPCR, correlation analysis in clinical samples\",\n      \"journal\": \"PeerJ\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single knockdown experiment demonstrating ELK1→NDUFA4L2 regulation; single lab, single method\",\n      \"pmids\": [\"29158991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In hypoxic pulmonary artery smooth muscle cells, NDUFA4L2 (downstream of HIF-1α) promotes ROS-mediated lipid peroxidation (MDA and 4-HNE accumulation) and activates a p38–5-lipoxygenase downstream signaling pathway to drive PASMC proliferation and vascular remodeling; siNDUFA4L2 blocks these effects.\",\n      \"method\": \"NDUFA4L2 siRNA knockdown in human PASMCs, MDA/4-HNE measurement, ROS assay, 5-LO/p38 pathway western blot, in vivo hypoxic PAH rat model\",\n      \"journal\": \"Journal of Cellular and Molecular Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with multiple pathway-specific biochemical readouts (ROS, lipid peroxides, p38-5-LO); in vivo model corroboration; single lab\",\n      \"pmids\": [\"33340241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Ndufa4l2 knockdown in renal proximal tubules of a TRACK mouse model reduces neutral lipid accumulation and decreases expression of ccRCC markers carbonic anhydrase 9 (CA9) and Enolase 1 (ENO1), linking mitochondrial NDUFA4L2 to lipid deposition and ccRCC marker expression.\",\n      \"method\": \"Dox-inducible shRNA-mediated knockdown of Ndufa4l2 in transgenic mouse kidney (TRACK model), lipid staining, CA9 and ENO1 protein quantification\",\n      \"journal\": \"Frontiers in Oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo tissue-specific knockdown with defined biochemical phenotype; single lab, single genetic model\",\n      \"pmids\": [\"34970493\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"COXFA4L2 (NDUFA4L2) is a nuclear-encoded mitochondrial protein whose expression is transcriptionally induced by HIF-1α (via HRE binding) and additional transcription factors (ELK1, NFIB); it functions primarily as an inhibitor of mitochondrial respiratory Complex I activity to reduce oxygen consumption and ROS production under hypoxia, acts as a compensatory paralog of COXFA4 at Complex IV when COXFA4 is lost, regulates mitochondrial fragmentation and mitochondrial-lysosomal associations, promotes a Warburg-like metabolic shift, and activates downstream signaling (PI3K/AKT, p38-5-LO) to influence cell survival, muscle mass, vascular remodeling, and cancer drug resistance.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"COXFA4L2 (NDUFA4L2) is a nuclear-encoded mitochondrial protein that serves as a hypoxia-driven brake on oxidative metabolism, restraining electron transport chain activity to limit oxygen consumption and reactive oxygen species (ROS) production [#0, #7]. Its expression is a direct transcriptional output of the HIF pathway: HIF-1\\u03b1 binds the hypoxia response element of the NDUFA4L2 promoter [#2], and PHD2/PHD3-dependent HIF stabilization controls its constitutive, cell-type-restricted expression in brain pericytes and mural cells, where loss of the protein raises oxygen consumption and amplifies the cellular hypoxia response [#7]. Mechanistically, COXFA4L2 inhibits respiratory Complex I activity without altering ETC protein content, and its loss restores Complex I flux with consequent mitoROS accumulation and apoptosis [#0, #4, #11]. This metabolic restraint produces a Warburg-like shift toward glycolysis and reshapes mitochondrial dynamics, promoting mitochondrial fragmentation and mitochondrial\\u2013lysosomal associations [#9]. Across many disease settings the same ROS-suppressive function is co-opted: it confers cytoprotection in cardiomyocytes and cardiac stem cells under hypoxia/reperfusion [#1, #2], drives proliferation and vascular remodeling in pulmonary artery smooth muscle cells via a p38\\u20135-lipoxygenase axis [#16], promotes reactive gliosis through PI3K/AKT signaling in retinal M\\u00fcller cells [#13], and underlies tumor growth and resistance to multiple anticancer agents by suppressing ROS-mediated cell death [#5, #6, #14]. Beyond its respiratory inhibitory role, COXFA4L2 is a paralog of the Complex IV subunit COXFA4 (NDUFA4) and is upregulated to functionally compensate for COXFA4 loss, preserving residual cytochrome c oxidase activity in patient-derived fibroblasts from individuals with biallelic COXFA4-null Leigh-like encephalopathy [#12].\",\n  \"teleology\": [\n    {\n      \"year\": 2011,\n      \"claim\": \"Established the founding mechanism: how does a HIF target gene help cells survive hypoxia metabolically? COXFA4L2 was shown to inhibit Complex I, lowering O2 consumption and ROS.\",\n      \"evidence\": \"RNAi silencing and knockout MEFs with oxygen consumption and Complex I activity assays\",\n      \"pmids\": [\"22100406\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of Complex I inhibition (binding site, stoichiometry) not defined\", \"Does not address whether the protein associates with Complex I or acts indirectly\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Tested whether the ROS-suppressive function is exploited by tumors; NDUFA4L2 inactivation raised mitochondrial activity, ROS, and apoptosis and impaired HCC growth/metastasis.\",\n      \"evidence\": \"siRNA knockdown, oxygen consumption/ROS/apoptosis assays, orthotopic HCC mouse model, HIF inhibitor\",\n      \"pmids\": [\"26819450\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular target within mitochondria not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved the direct transcriptional control: HIF-1\\u03b1 binds the NDUFA4L2 HRE to activate it, and this supports cell survival under hypoxia.\",\n      \"evidence\": \"ChIP for HIF-1\\u03b1 at the HRE, HIF agonist/inhibitor, siRNA knockdown and viability assays in cardiac stem cells\",\n      \"pmids\": [\"29953852\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not address additional transcription factor inputs\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Probed cytoprotection mechanism in cardiomyocytes; overexpression prevented hypoxia/reperfusion apoptosis and mitochondrial dysfunction, with Complex I silencing recapitulating the effect to establish epistasis.\",\n      \"evidence\": \"Overexpression/knockdown in H9c2 cells with apoptosis, ATP, mPTP, and cytochrome c assays\",\n      \"pmids\": [\"28429857\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo cardiac validation\", \"Not independently replicated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Began mapping upstream regulators beyond HIF; ELK1 was shown to positively regulate NDUFA4L2 in ccRCC.\",\n      \"evidence\": \"ELK1 knockdown with NDUFA4L2 readout and clinical correlation\",\n      \"pmids\": [\"29158991\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single knockdown experiment, single method\", \"No direct promoter binding demonstrated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended the survival role to oxidative-stress contexts; NDUFA4L2 limits apoptosis by suppressing excessive mitophagy in nucleus pulposus cells.\",\n      \"evidence\": \"Primary NP cells, TBHP oxidative stress, mitophagy inhibitor rescue, gain/loss of function, in vivo IVDD model\",\n      \"pmids\": [\"31740659\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link between Complex I inhibition and mitophagy regulation not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified a downstream signaling consequence of NDUFA4L2-driven ROS; in PASMCs it engages a p38\\u20135-lipoxygenase pathway and lipid peroxidation to drive proliferation and vascular remodeling.\",\n      \"evidence\": \"siRNA knockdown in human PASMCs, MDA/4-HNE/ROS assays, p38-5-LO western blots, hypoxic PAH rat model\",\n      \"pmids\": [\"33340241\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How ROS selectively activates p38-5-LO unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated direct mitochondrial localization tied to function; NDUFA4L2 facilitates HER2 mitochondrial relocalization and suppresses ROS to drive trastuzumab resistance.\",\n      \"evidence\": \"Immunofluorescence and mitochondrial fractionation, Seahorse, DCFDA ROS, overexpression, resistance assays\",\n      \"pmids\": [\"34276814\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical interaction with HER2 not established\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided in vivo gain-of-function evidence in skeletal muscle, linking metabolic restraint to muscle wasting; ectopic expression reduced respiration/ROS, depleted nucleotide pools, and caused muscle mass loss with atrogene/apoptotic gene induction.\",\n      \"evidence\": \"Adenoviral/electroporation expression in mouse muscle, femoral artery ligation, respiration and metabolite measurements, muscle force\",\n      \"pmids\": [\"34724256\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether endogenous induction reaches pathogenic thresholds in disease unclear\", \"Molecular trigger of atrogene program not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected NDUFA4L2 to the ccRCC phenotype in vivo; knockdown reduced renal lipid accumulation and ccRCC markers CA9 and ENO1.\",\n      \"evidence\": \"Dox-inducible shRNA knockdown in TRACK transgenic mouse kidney, lipid staining, marker quantification\",\n      \"pmids\": [\"34970493\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal mechanism linking respiration inhibition to lipid deposition not resolved\", \"Single genetic model\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined cell-type-specific expression and its physiological coupling to hypoxia sensing; NDUFA4L2 is pericyte/mural-cell enriched, PHD2/3-HIF controlled, and tunes O2 consumption against the HIF response.\",\n      \"evidence\": \"scRNA-seq, multiplexed FISH, Ng2-cre Vhl conditional knockout, pericyte O2 consumption and HIF reporter assays\",\n      \"pmids\": [\"35929074\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological role in neurovascular function not directly tested\", \"Does not address Complex I vs other respiratory targets in pericytes\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Added transcriptional and post-translational regulators in cancer; NFIB binds the promoter to induce NDUFA4L2 (sorafenib resistance), and NXPH4 stabilizes the protein to drive glycolysis/ROS (gemcitabine resistance).\",\n      \"evidence\": \"Promoter binding assays, NFIB and NXPH4 knockdown with rescue, ROS/glycolysis assays, in vivo tumor models\",\n      \"pmids\": [\"36369883\", \"35954445\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of NXPH4-mediated protein stabilization unknown\", \"Direct vs indirect promoter binding by NFIB not fully resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Broadened the cellular role beyond Complex I; proteomics and imaging linked NDUFA4L2 to a Warburg-like shift, mitochondrial fragmentation, and mitochondrial-lysosomal associations including NPC1/NPC2.\",\n      \"evidence\": \"CRISPR KO (RCC4), co-IP MS proteomics, Seahorse, high-resolution live-cell microscopy\",\n      \"pmids\": [\"36722045\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The very large co-IP interactome (3,215 proteins) lacks specificity filtering for direct partners\", \"Functional significance of NPC1/NPC2 association not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Uncovered new downstream effector axes; miR-183-5p directly targets NDUFA4L2 to release Complex I and raise mitoROS in LUSC, and a NDUFA4L2\\u2192IL-33\\u2192PADI4/NET axis inhibits cuproptosis to drive lenvatinib resistance in HCC.\",\n      \"evidence\": \"miR overexpression/knockdown with Complex I and mitoROS assays; IL-33/NET/cuproptosis assays with mTOR and PADI4 inhibitors, in vivo HCC models\",\n      \"pmids\": [\"39154121\", \"39585643\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How NDUFA4L2 induces IL-33 production mechanistically unclear\", \"Single lab for each axis\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Revealed a distinct Complex IV role; as a COXFA4 paralog, COXFA4L2 is upregulated to compensate for COXFA4 loss and preserve COX activity in COXFA4-null patient cells.\",\n      \"evidence\": \"Patient-derived fibroblasts (13 individuals), COX activity and assembly assays, COXFA4L2 protein quantification\",\n      \"pmids\": [\"42218136\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether COXFA4L2 is a constitutive Complex IV subunit or only a compensatory substitute unclear\", \"Relationship between Complex I inhibitory and Complex IV roles not reconciled\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Established a signaling output in retinal disease; Ndufa4l2 activates PI3K/AKT to drive Muller cell gliosis, proliferation, and migration under ischemia.\",\n      \"evidence\": \"scRNA-seq (OIR model), CRISPR KO/overexpression, PI3K inhibitor (LY294002) rescue, in vitro and in vivo validation\",\n      \"pmids\": [\"42235340\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How a mitochondrial respiratory regulator activates PI3K/AKT not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural and biochemical basis by which COXFA4L2 inhibits Complex I versus functions at Complex IV remains unresolved, as does how a single mitochondrial protein produces such diverse downstream signaling (PI3K/AKT, p38-5-LO, IL-33/NET) outputs.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure or direct binding partner within Complex I established\", \"Whether respiratory inhibition and Complex IV compensation are the same protein pool unknown\", \"Mechanism linking metabolic restraint to specific cytoplasmic signaling cascades unclear\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 11]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 5, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 9, 4]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12, 14, 16]}\n    ],\n    \"complexes\": [\n      \"Mitochondrial respiratory Complex I (inhibitory regulator)\",\n      \"Cytochrome c oxidase / Complex IV (compensatory subunit)\"\n    ],\n    \"partners\": [\n      \"COXFA4\",\n      \"NXPH4\",\n      \"HER2\",\n      \"NPC1\",\n      \"NPC2\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}